Kestra Showcases Real-World Outcomes for ASSURE WCD at Heart Rhythm 2025

Rhea-AI Summary

Kestra Medical Technologies presented new real-world data for their ASSURE Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025 in San Diego. The study focused on outcomes in a community-based setting using an advanced practice provider (APP)-driven protocol.

Key findings demonstrate:

• High patient compliance with 23.3 hours median daily wear time
• Consistent usage beyond 90 days
• 4% of patients showed ventricular arrhythmias detection
• Successful implementation of APP-driven care model
• Effective continuity of care through ICD placement or hospitalization when needed

The study validates ASSURE's effectiveness in protecting patients from sudden cardiac arrest through both clinical performance and patient engagement. The results highlight the success of structured, team-based approaches in expanding access to cardiac care within community settings.

Positive

• High patient compliance with 23.3 hours median daily wear time demonstrates strong product adoption
• Successful arrhythmia detection in 4% of patients validates product effectiveness
• APP-driven care model proves scalability in community settings, potentially reducing operational costs
• Evidence of effective continuity of care through successful patient transitions to ICD placement
• Strong real-world data supporting product performance could drive market adoption

Negative

• None.

New data highlights strong wear compliance, meaningful arrhythmia detection, and continuity of care in community-based advanced practice provider-driven model

KIRKLAND, Wash., April 29, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, today announced the presentation of new real-world data on the ASSURE^® Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025, the annual meeting of the Heart Rhythm Society (HRS), held April 24–27 in San Diego.

The abstract, titled “Real-world Experience with a Novel Wearable Cardioverter Defibrillator in a Community Setting: Advanced Practice Provider-Driven Care Model,” was developed in partnership with Ashley L. Dailey, ANP-BC, MSN and Opesanmi O. Esan, MD, and presented at the annual meeting. The abstract examined outcomes in a nonprofit, community-based medical center using an advanced practice provider (APP)-driven protocol for WCD therapy—one of the first analyses of its kind.

“The data reinforce how the ASSURE system supports meaningful protection from sudden cardiac arrest through both clinical performance and patient engagement—particularly in real-world, community care settings,” said Brian Webster, President and Chief Executive Officer of Kestra. “We were proud to see this work highlighted at HRS.”

Key Findings from the Abstract
The analysis revealed high patient compliance, with a median daily wear time of 23.3 hours and consistent usage, often extending beyond 90 days—highlighting the importance of sustained device use in protecting patients at risk of sudden cardiac death.

Notably, ventricular arrhythmias were detected in 4% of patients, even within a predominantly primary prevention population, underscoring the importance of real-time monitoring and early intervention. Among those who received therapy, the outcomes reflect effective continuity of care—with patients benefiting from timely escalation through ICD placement or hospitalization.

Additionally, the study highlighted how an APP-driven care model successfully delivered WCD therapy in alignment with guideline-based recommendations—ensuring that all indicated patients received appropriate care and demonstrating the value of structured, team-based approaches in expanding access and improving outcomes within a community-based setting. View the full abstract here.

The presentation marked another milestone for Kestra and its mission to expand access to intelligent, connected cardiac recovery solutions across all levels of care.

About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.

Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com

Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

FAQ

What are the key results from Kestra's ASSURE WCD study presented at Heart Rhythm 2025?

The study showed high patient compliance with 23.3 hours median daily wear time, detected ventricular arrhythmias in 4% of patients, and demonstrated successful implementation of an advanced practice provider-driven care model in community settings.

How effective is the ASSURE Wearable Cardioverter Defibrillator in real-world settings?

The ASSURE WCD showed strong effectiveness with patients wearing it for 23.3 hours daily, often beyond 90 days, and successfully detecting ventricular arrhythmias in 4% of patients, leading to timely interventions through ICD placement or hospitalization.

What makes Kestra's (KMTS) ASSURE WCD different in community-based healthcare?

The ASSURE WCD successfully implements an advanced practice provider-driven protocol in community settings, ensuring guideline-based care delivery and improving access to cardiac monitoring through structured, team-based approaches.

What is the patient compliance rate for Kestra's ASSURE Wearable Cardioverter Defibrillator?

Patients showed high compliance with the ASSURE WCD, maintaining a median daily wear time of 23.3 hours and consistent usage extending beyond 90 days.

How does Kestra's ASSURE WCD support sudden cardiac arrest prevention?

The ASSURE system provides protection through real-time monitoring, early detection of ventricular arrhythmias, and ensures continuity of care through timely escalation to ICD placement or hospitalization when needed.